ACCURAY INCORPORATED (NASDAQ:ARAY) Files An 8-K Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial
Condition.

On April 27, 2017, Accuray Incorporated (the Company) issued a
press release announcing its financial results for the quarter
ended March 31, 2017. A copy of the Companys press release dated
April 27, 2017, titled Accuray Third Quarter Gross Orders
Increase 49% YoY; Backlog Up 21% is attached hereto as
Exhibit99.1 and is incorporated herein by reference.

The foregoing information (including Exhibit 99.1 hereto) is
being furnished under Item2.02 Results of Operations and
Financial Condition and shall not be deemed filed for purposes of
Section18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933, as amended (the
Securities Act), or the Exchange Act, except as shall be
expressly set forth by specific reference in such filing.

Item 5.02 Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.

On April 24, 2017, the Company decided to eliminate the role of
Chief Operating Officer following the conclusion of fiscal 2017.
As a consequence, Kelly Londy, the Companys Executive Vice
President, Chief Operating Officer, will be leaving the Company
on July 5, 2017.

Item 7.01 Regulation FD
Disclosure.

On April 27, 2017, the Company issued a press release announcing
the appointment of Lionel Hadjadjeba as Senior Vice President,
Chief Commercial Officer, and the impending elimination of the
Companys Chief Operating Officer role. The press release is
furnished as Exhibit99.2 to this Current Report on Form8-K. In
accordance with General Instruction B.2 of Form8-K, the
information in Exhibit99.2 and in this Item shall not be deemed
to be filed for purposes of Section18 of the Exchange Act, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act or the Exchange Act, except as shall be
expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and
Exhibits.

(d)Exhibits

About ACCURAY INCORPORATED (NASDAQ:ARAY)

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

ACCURAY INCORPORATED (NASDAQ:ARAY) Recent Trading Information

ACCURAY INCORPORATED (NASDAQ:ARAY) closed its last trading session down -0.20 at 4.60 with 540,434 shares trading hands.